HER2-positive early breast cancer is a heterogenous disease. We assessed the role of body mass index (BMI) and hormone receptors (HRs) in 238 women who completed adjuvant chemotherapy and 1 year of treatment with trastuzumab. Three-year recurrence risk resulted as higher for HR-negative (HR−) patients with BMI ≥25 compared with HR+ patients with BMI <25, suggesting that this particular subpopulation of patients might benefit from escalation approaches in adjuvant treatment.
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients / Cantini, L.; Pistelli, M.; Merloni, F.; Fontana, A.; Bertolini, I.; De Angelis, C.; Bastianelli, L.; Della Mora, A.; Santinelli, A.; Savini, A.; Maccaroni, E.; Diodati, L.; Falcone, A.; Berardi, R.. - In: CLINICAL BREAST CANCER. - ISSN 1526-8209. - 20:1(2020), pp. e89-e98. [10.1016/j.clbc.2019.06.008]
Body Mass Index and Hormone Receptor Status Influence Recurrence Risk in HER2-Positive Early Breast Cancer Patients
Cantini L.;Pistelli M.;Merloni F.;Bastianelli L.;Della Mora A.;Santinelli A.;Savini A.;Maccaroni E.;Berardi R.
2020-01-01
Abstract
HER2-positive early breast cancer is a heterogenous disease. We assessed the role of body mass index (BMI) and hormone receptors (HRs) in 238 women who completed adjuvant chemotherapy and 1 year of treatment with trastuzumab. Three-year recurrence risk resulted as higher for HR-negative (HR−) patients with BMI ≥25 compared with HR+ patients with BMI <25, suggesting that this particular subpopulation of patients might benefit from escalation approaches in adjuvant treatment.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
